Navigation Links
Soligenix Announces Preliminary Results of its Phase 2 Clinical Trial of orBec® in the Prevention of Acute GVHD
Date:10/25/2010

ctive steroid therapy, like orBec®, could have an impact on preventing the development of GVHD very early in the disease process," added Brian L. Hamilton, MD, PhD, Chief Medical Officer of Soligenix.  "The trend towards less severe acute GVHD in the patients treated with orBec® is encouraging. We are continuing to analyze the Phase 2 data for other clinically meaningful signals."

Dr. Hamilton continued, "We obviously remain confident in the ultimate success of our confirmatory Phase 3 study of orBec® in the treatment of acute GI GVHD. This Phase 3 trial is anchored by more than 15 years of clinical research in the treatment setting, including positive results from two prior randomized, double-blind, placebo-controlled studies.  The current Phase 3 study is designed to replicate the endpoint of treatment failure rate at Study Day 80, which was successfully measured as a secondary endpoint (p-value 0.005) in the Company's previous Phase 3 study.  Accordingly, there is no correlation between the prospects for success in these distinctly different therapeutic indications and patient populations.  We continue to make good progress towards completing the confirmatory Phase 3 trial in treatment of acute GI GVHD in the second half of next year."

About orBec®

orBec®, oral beclomethasone dipropionate (oral BDP), is currently the subject of a confirmatory Phase 3 clinical trial in the treatment of acute GI GVHD. This Phase 3 trial, also referred to as the SUPPORTS protocol (Sparing Unnecessary Prednisone Phase 3 orBec® Randomized Treatment Study), will enroll an estimated 166 patients to confirm the clinically meaningful endpoints observed in previous Phase 2 and Phase 3 clinical studies. The primary endpoint is the treatment failure rate at Study Day 80. This endpoint was successfully measured as a secondary endpoint (p-value 0.005) in
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Soligenix Announces Publication of Positive Stability Results with RiVax(TM), its Vaccine Against Ricin Toxin
2. Soligenix Announces Publication of Positive Pre-Clinical Results with RiVax(TM), Its Vaccine Against Ricin Toxin
3. Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis
4. Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines
5. Soligenix Announces Issuance of Hong Kong Patent for its LPM(TM) Oral Drug Delivery Technology
6. Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration
7. Soligenix to Present at the OneMedForum Conference on Wednesday, June 30 at 2PM EDT
8. Soligenix Announces Award of $1.2 Million FDA Orphan Products Development Grant
9. Soligenix to Present at the Rodman & Renshaw Healthcare Conference on September 15, 2010 at 10AM EDT
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015 Vermillion, Inc. (VRML), a ... announced today it will report its second ... close on Thursday, August 13, 2015, followed ... at 4:30pm Eastern.Conference Call and Webcast:  ... Pacific  Domestic: , 888-430-8691International: ...
(Date:7/30/2015)... 2015 What can be expected ... are going to grow at the fastest rates? ... to 2025, assessing data, trends, opportunities and prospects there. ... tables, charts, and graphs. Discover the most lucrative areas ... new study lets you assess forecasted sales at overall ...
(Date:7/30/2015)... July 30, 2015  Cleave Biosciences today announced ... has granted the company a key patent providing ... molecule CB-5083. This newly issued patent, ... p97," U.S. 9,062,026, allows for claims on the ... selective oral inhibitor of p97, a critical enzyme ...
Breaking Medicine Technology:Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 2Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 3Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 4Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 5Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 6
... a medical device,company specializing in applications that ... device has received CE approval in Europe ... the first hands-free,patch-based device that uses surface ... innovative PainShield consists of a disposable patch,connected ...
... BioSciences and Arisyn Therapeutics jointly announced today the ... of Health to support the development of novel ... C virus (HCV) infection. ImQuest scientists will ... of ATI-0810 (Formerly PG301029) and a series of ...
Cached Medicine Technology:NanoVibronix Receives Wound Healing Indications in Europe for its PainShield(TM) Device 2ImQuest BioSciences Receives Phase I SBIR Grant to Develop a Novel Hepatitis C Virus Therapeutic Agent 2
(Date:7/30/2015)... ... 30, 2015 , ... The connection between a healthy head of hair and a feeling of ... full head of hair can have a devastating impact on the daily life of a ... work place, the consequences of hair loss are not to be taken lightly. , The ...
(Date:7/30/2015)... York, NY (PRWEB) , ... July 30, 2015 ... ... Setria®Glutathione and Sustamine® L-Alanyl-L-Glutamine for people on the go. With no water needed, ... Recovery Chewable as a simple way to get the natural ingredients that may ...
(Date:7/30/2015)... ... 2015 , ... Eyepartner is proud to highlight that their ... Gaslamp Quarter Plaza for five years this September. , The surveillance and ... any suspicious activity. These cameras are in place to provide inarguable proof in ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... scientific program at ATA’s 21st Annual Meeting and Tradeshow focused exclusively on telemedicine, ... than 300 cutting-edge health care technology vendors, will take place May 14-17, 2016 ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... into one of the largest, family-owned low cost service and repair companies. For ... applications, as well as growing their company to meet the demands of the ...
Breaking Medicine News(10 mins):Health News:New Study Shows the Link between Hair Restoration and Healthy Self-Image 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 3Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 4Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 2Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 3Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 3Health News:Bill Howe Plumbing, Heating & Air Launches Online Application to Prospective Employees 2Health News:Bill Howe Plumbing, Heating & Air Launches Online Application to Prospective Employees 3
... SearchMedica.com,( http://www.searchmedica.com/ ), the leading search engine ... channel. The search,channel connects radiologists and other medical ... imaging resources. , ... some point,no matter what their specialty," said Edward ...
... of Warwick have discovered high doses of thiamine vitamin ... disease. , Kidney disease, or diabetic nephropathy, develops progressively in ... is assessed by a high excretion rate of the protein ... , The research is led by Dr Naila Rabbani and ...
... of Medicine (BUSM) is one of seven centers to ... Health (NIH) to use cutting edge genomic technologies to ... BUSM will fund a study to probe the causes ... with smoking that is characterized by airflow limitation. ...
... LifeCare Holdings, Inc., today,announced the appointment of Diane H. ... term acute care hospital system. She will report to,Phillip ... A proven sales and marketing leader, ... including experience in senior,marketing, business development and operational roles ...
... should not determine whether an older patient with acute ... cell transplant from a matched donor, researchers of the ... today at the 50th annual meeting of the American ... just as well as younger patients with transplants that ...
... copayments for generic prescriptions from Jan 1 - June 30, 2009; BCBSNC,s ... save a total of $13 million on out-of-pocket costs; The 2009 generic ... ... Chapel Hill, NC (Vocus) December 8, 2008 -- Blue Cross and ...
Cached Medicine News:Health News:SearchMedica Launches Radiology Search Channel for Medical Professionals 2Health News:Vitamin B1 could reverse early-stage kidney disease in diabetes patients 2Health News:Boston University School of Medicine receives a grant to study chronic obstructive pulmonary disease 2Health News:Older age doesn't affect survival after bone marrow transplant 2Health News:BCBSNC Helps Customers Fight Recession With Free Generics 2Health News:BCBSNC Helps Customers Fight Recession With Free Generics 3Health News:BCBSNC Helps Customers Fight Recession With Free Generics 4
... DiscoverySE Centrifuges. Workhorse. All in one. ... the new Sorvall Discovery 100SE Ultracentrifuge ... features come with top-of-the-line performance, powerful ... all built into the smallest, quietest, ...
... DiscoveryTMM150 SE Micro-ultra centrifuge continues to raise ... processing, now with 1,048,000 x g performance ... DiscoveryTMM150SE processes sample sizes from 0.2 ... floor footprint, brushless direct drive, very quiet ...
... the highest g-force ever. But optimal productivity ... Optima MAX combines maximum force, capacity, and ... that's worlds apart from any other system. ... enhanced efficiency, Optima takes productivity to the ...
... Efficiency, versatility, and environmental safety ... Optima LE-80 K Ultracentrifuge from ... innovative Optima centrifugation technology, the ... cost effectively provide advanced capability ...
Medicine Products: